Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Operating Leases (2022 - 2025)

Altimmune (ALT) has disclosed Operating Leases for 3 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 16.92% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a 16.92% decrease, with the full-year FY2024 number at $1.4 million, up 701.14% from a year prior.
  • Operating Leases was $1.2 million for Q3 2025 at Altimmune, down from $1.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.5 million in Q2 2024 to a low of $44000.0 in Q1 2024.
  • A 3-year average of $1.1 million and a median of $1.3 million in 2025 define the central range for Operating Leases.
  • Biggest YoY gain for Operating Leases was 2950.0% in 2025; the steepest drop was 16.92% in 2025.
  • Altimmune's Operating Leases stood at $175000.0 in 2023, then skyrocketed by 701.14% to $1.4 million in 2024, then fell by 13.48% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Operating Leases are $1.2 million (Q3 2025), $1.3 million (Q2 2025), and $1.3 million (Q1 2025).